Literature DB >> 7786396

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs.

G R Pettit1, C Temple, V L Narayanan, R Varma, M J Simpson, M R Boyd, G A Rener, N Bansal.   

Abstract

Combretastatin A-4 (1a), the principal cancer cell growth-inhibitory constituent of the Zulu medicinal plant Combretum caffrum, has been undergoing preclinical development. However, the very limited water solubility of this phenol has complicated drug formation. Hence, derivatives of the combretastatin A-4 (1a) 3'-phenol group were prepared for evaluation as possible water-soluble prodrugs. As observed for combretastatin A-4, the sodium salt (1b), potassium salt (1c) and hemisuccinic acid ester (1e) derivatives of phenol 1a were essentially insoluble in water. Indeed, these substances regenerated combretastatin A-4 upon reaction with water. A series of other simple derivatives (1d, 1f-j) proved unsatisfactory in terms of water solubility or stability, or both. The most soluble derivatives evaluated included the ammonium (1l), potassium (1m) and sodium (1n) phosphate salts, where the latter two proved most stable and suitable. Both the potassium (1m) and sodium (1n) phosphate derivatives of combretastatin A-4 were also found to exhibit the requisite biological properties necessary for a useful prodrug. Sodium salt 1n was selected for drug formulation and further pre-clinical development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786396

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  45 in total

1.  Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.

Authors:  R M Hartley; J Peng; G A Fest; S Dakshanamurthy; D E Frantz; M L Brown; S L Mooberry
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

2.  Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.

Authors:  Cheng-Huang Shen; Jia-Jen Shee; Jin-Yi Wu; Yi-Wen Lin; Jiann-Der Wu; Yi-Wen Liu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 3.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

4.  Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles in vitro and in vivo.

Authors:  Zhenhua Huang; Gentao Li; Xue Wang; Hu Xu; Youcai Zhang; Qingzhi Gao
Journal:  Medchemcomm       Date:  2017-06-12       Impact factor: 3.597

Review 5.  Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

Authors:  Zaki S Seddigi; M Shaheer Malik; A Prasanth Saraswati; Saleh A Ahmed; Ahmed O Babalghith; Hawazen A Lamfon; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

6.  Novel hybrid nocodazole analogues as tubulin polymerization inhibitors and their antiproliferative activity.

Authors:  Sangram S Kale; Ganesh S Jedhe; Sachin N Meshram; Manas K Santra; Ernest Hamel; Gangadhar J Sanjayan
Journal:  Bioorg Med Chem Lett       Date:  2015-03-14       Impact factor: 2.823

7.  Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Valerio Bertolasi; Michela Cancellieri; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Francesca Consolaro; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2014-07-28       Impact factor: 7.446

8.  Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Authors:  Yu-Chen Cai; Yong Zou; Yan-Li Ye; Hong-Yi Sun; Quan-Guan Su; Zhi-Xin Wang; Zhao-Lei Zeng; Li-Jian Xian
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

9.  Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors:  Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal:  Molecules       Date:  2017-08-31       Impact factor: 4.411

10.  Design and synthesis of 2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one analogues as potent antitumor agents that inhibit tubulin assembly.

Authors:  Yu-Hsun Chang; Mei-Hua Hsu; Sheng-Hung Wang; Li-Jiau Huang; Keduo Qian; Susan L Morris-Natschke; Ernest Hamel; Sheng-Chu Kuo; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.